Here are 19 key notes on orthopedic and spine device companies over the past week.
Amedica responded to the FDA inquiries about the company's cervical composite silicon nitride interbody device and received feedback on wear testing for femoral head protocols.
BioRestorative Therapies announced a reverse split of its common stock in preparation for its planned listing on the NASDAQ Capital Market.
Captiva Spine received 510(K) clearance from the FDA for its enhanced TowerLOX MIS Pedicle Screw System.
ConforMIS closed its initial public offering.
ECA Medical Instruments developed the first single-procedure surgical ratchet for orthopedic and spine implants.
FzioMed has shipped 400,000 units of Oxiplex gel.
FUJIFILM SonoSite made changes in its executive leadership — Naohiro Fujitani was named chairman and Masayuki Higuchi was named president and CEO.
Interventional Spine appointed Joseph Darling vice president and COO.
K2M launched six new products in Singapore and Hong Kong — including the MESA Deformity Spinal System with two minimally invasive offerings; EVEREST Minimally Invasive Spinal System and TERRA NOVA Minimally Invasive Access System.
K2M reported second quarter revenue increase in their preliminary report, but the estimated net loss for the quarter is expected to hit $6.5 million to $8.5 million.
K2M also announced a proposed common stock offering — The company will offer 750,000 shares and the selling stockholders named in the registration statement will sell 3.75 million shares.
LDR appointed Alan Milinazzo to its board of directors as a Class I director, effective immediately.
Materialise expanded its partnership with Consensus Orthopedics to include the Materialise Acetabular Cup Orientation Hip Guide.
Mazor Robotics appointed Anat Kaphan vice president of marketing and product management.
Mazor Robotics also reported that the company received purchase orders for seven Renaissance Systems during second quarter of 2015.
NuVasive elected Daniel J. Wolterman to its board of directors.
OrthoSpace enrolled the first three patients in its United States investigational device exemption pivotal study.
SeaSpine completed its spin-off from Integra LifeSciences and the company has a strong balance sheet with $47 million of cash and no debt post-spin-off.
SpineGuard reported revenue growth for the first half of 2015 — the company's revenue grew 41 percent in the first halve of the year over the same period last year.